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Background: Tigecycline (TIG), a new glycylcycline
demonstrates enhanced activity against many multi-
drug resistant phenotypes of community and nosocomial
pathogens causing serious disease. The T.E.S.T. program was
designed to elucidate the activity of TIG vs. comparators in
clinical use to worldwide organisms.
Methods: Between 2004—2007, over 3880 organisms
deemed clinically signiﬁcant isolated from both inpatients
and outpatients in 23 Asia/Paciﬁc Rim centers underwent
site directed CLSI speciﬁed MIC testing utilizing supplied
broth microdilution panels.
Results: Selected Asia/Paciﬁc Rim pathogens tested
against TIG are shown below: Conclusions: Tigecycline MIC90
of ≤1mcg/ml and % susceptible of 100% (at ≤2mcg/ml B.P.)
for gram positive pathogens (including resistant phenotypes)
and MIC90 of ≥95% of gram negative pathogens (excluding P.
aeruginosa) validate the potent activity of TIG against com-
munity/hospital pathogens isolated in 23 Asia/Paciﬁc Rim
centers.
doi:10.1016/j.ijid.2008.05.1075
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Background: Tigecycline (TIG), a member of a new class
of antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most
commonly encountered species responsible for commu-
nity and hospital acquired infections. The T.E.S.T. program
determined the in vitro activity of TIG compared to
amoxicillin-clavulanic acid, piperacillin-tazobactam (PT),
levoﬂoxacin, ceftriaxone, cefepime, ampicillin (AMP),
amikacin (AK), minocycline, ceftazidime and imipenem
(IMP) against ESBL isolates collected from hospitals globally
throughout 2004—2007.
Methods: A total of 1,387 ESBL clinical isolates were
identiﬁed to the species level from participating site and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentrations (MICs) were determined by the local lab-
oratory using supplied broth microdilution panels and
interpreted according to CLSI guidelines with tigecycline
susceptible breakpoint deﬁned as ≤2mcg/mL
Results: %S for all ESBL-producing isolates vs. TIG, IMP,
and AK was 94.1, 98.3, and 86.2%, respectively; %S for other
comparators ranged from 61.2% (PT) to 0.6% (AMP).TIG and
IMP had the lowest % of resistant strains(1.8% and 0.7%)
respectively compared to 6.9% for AK. MIC50/90 for TIG, IMP,
and AK were 0.5/2, 0.25/1, and 4/32mcg/ml; the MIC90 for
all other drugs was in the resistant range. There were minor
regional differences in levels of activity, with either TIG
(North America) or IMP (Europe, Asia/Pac) being the most
active
Conclusions: TIG exhibited similar in vitro as IMP against
ESBL strains. Its expanded broad spectrum of activity,
including strains resistant or multiply-resistant to other
agents, should make it a useful treatment option for a wide
range of gram-negative and gram-positive pathogens.
doi:10.1016/j.ijid.2008.05.1076
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Background: Tigecycline (TIG) has potent expanded
broad spectrum activity against most commonly encoun-
tered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the in
vitro activity of TIG against Acinetobacter resistant to one
or more of piperacillin-tazobactam (PT), levoﬂoxacin (LVX),
ceftriaxone (CAX), cefepime (CPE), amikacin (AK), minocy-
cline (MIN), ceftazidime (CAZ), and imipenem (IMP). Study
strains were collected from hospitals in the United States
from 2004—2007.
Methods: A total of 2,367 clinical isolates were identiﬁed
to species level from participating sites and conﬁrmed by
the central laboratory. Minimum Inhibitory Concentrations
(MICs) were determined by the local laboratory using sup-
plied broth microdilution panels and interpreted according
to CLSI guidelines
Results: Resistance rates for comparator drugs were CAZ
42%, CAX 41%, LVX 41%, CPE 34%, PT 17%, AK 7%, MIN 7%,
and IMP 2%. TIG inhibited 98% of all isolates at = 8mcg/ml.
TIG MIC50/90 for strains resistant to 0, 1, 2, 3, 4, or ≥5 drug
classes were 0.12/0.5, 0.5/1, 0.5/2, 1/2, 1/2, and 1/4,
respectively, demonstrating a gradual diminishment of TIG
activity in strains resistant to multiple drug classes
Conclusions: TIG had good in vitro activity against most
Acinetobacter strains resistant to one or more other drugs in
this study, although the higher TIG MICs seen for these strains
suggests some linkage to resistance mechanisms for other
drugs (efﬂux). TIG remained effective in inhibiting multi-
drug resistant Acinetobacter spp., further demonstrating its
wide spectrum of activity vs. drug-resistant bacteria.
doi:10.1016/j.ijid.2008.05.1077
